What does it take to build a truly global oncology company? On Cambridge Associates’ Unseen Upside podcast, our Co-founder, Chairman and CEO, @johnvoyler, talks about what it takes to turn a bold vision into global impact.
🎧 Listen to the conversation: https://t.co/Ov1DZSGoz3
I recently had the opportunity to discuss BeOne’s global capabilities on Cambridge Associates’ Unseen Upside podcast, including why we invested in building our own global development “superhighway” and what I’ve learned about the power of scientific collaboration across borders.
I hope you’ll listen to the conversation: https://t.co/llN64O3mTc
#UnseenUpside #Oncology #Innovation
We're proud to announce an expanded, multi-year partnership with @CllSociety to strengthen education, engagement and support across the CLL/SLL community.
For people living with CLL/SLL, having access to trusted, accurate information is essential to understanding their options and navigating treatment.
Together, we're advancing biomarker testing education and expanding access to digital resources and information to help patients, caregivers and healthcare professionals make more informed decisions about CLL/SLL care.
Learn more: https://t.co/7c6EIaIVf3
#News for #Investors and #Media: BeOne Medicines announces third quarter 2026 financial results and business updates.
Read the full press release here: https://t.co/1t0SNSpCTY
#News for #Investors and #Media: The U.S. FDA has granted priority review for our foundational BTK inhibitor in combination with rituximab for first-line mantle cell lymphoma (#MCL) patients. If approved, this BTKi-based regimen would be the first and only chemotherapy-free option for MCL patients in the United States. Full results from the Phase 3 MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting.
Read the full announcement: https://t.co/79mHZahWj4
#Oncology #BeOneInnovator
Adiós, Madrid. #ESMO2026 brought bold thinking, new science and a global oncology community together. We leave determined to keep changing the game through oncology innovation and pushing what’s possible for people with cancer.
Learn more: https://t.co/lykd1pw0SX
#TeamBeOne
#TeamBeOne shares what’s emerging at #ESMO26, their take on the science, and what it could mean for the field – and for patients.
Discover how we’re changing the game in solid tumor oncology: https://t.co/lykd1pw0SX
#TeamBeOne#FromFloorToFeed
#News for #Investors and #Media: At #ESMO2026, we’re presenting new data from across our advancing solid tumor pipeline, spanning four priority programs with distinct molecular approaches, highlighting the innovation and scale of our solid tumor portfolio.
Explore the data here: https://t.co/W03gAw4pWJ
#BeOneInnovator
#News for #Investors and #Media: At #ESMO26, we’re presenting a data from our Phase 3 trial evaluating our PD-1 inhibitor with a dual HER2-targeting bispecific antibody plus chemotherapy in HER2- positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) patients, supporting its use as a potential standard of care in first-line treatment of the condition.
Explore the data here: https://t.co/WY9G3N2oI7
#BeOneInnovator
¡Hola, Madrid! Just 1 day to go until #ESMO26. We look forward to spotlighting the momentum across our solid tumor pipeline and raising expectations where progress has been limited. Visit us at booth #8026, Hall 8.
Discover how we’re working to change the game in solid tumor oncology: https://t.co/NCCq0eubYO
#TeamBeOne #BeOneAgainstCancer
Cancer treatment has transformed. But progress in hepatocellular carcinoma (HCC) has been harder to achieve.
At BeOne, we believe changing the outlook starts with understanding what makes HCC different and pursuing science designed around the disease.
As new evidence emerges at #ESMO2026, we explore what it could take to move progress forward for patients.
Read more: https://t.co/bS4iMa1SBH
#BeOneAgainstCancer #LiverCancer
At #ESMO26, BeOne-supported research will explore a range of scientific topics across oncology, including novel therapeutic modalities, biomarker-driven approaches, early clinical development, and outcomes in specific patient populations.
Learn more about our scientific program on BeOne Medical: https://t.co/faWBXn1avT
#News for #Investors and #Media: The European Commission has granted our GPC3x4-1BB bispecific antibody Orphan Drug Designation for the treatment of hepatocellular carcinoma (HCC).
#LiverCancer#HCC#BeOneInnovator
#News for #Investors and #Media: At #ESMO26, we’re presenting 11 abstracts, including 9 posters and 2 oral presentations, highlighting the rapid advancement of our oncology pipeline.
We’re working to change the game in solid tumor oncology, with proof-of-concept assets advancing across our strategically focused disease areas.
Explore the data here: https://t.co/WGVRFcneaN
#BeOneInnovator
The treatment landscape for chronic lymphocytic leukemia (CLL) has shifted in fundamental ways, and the opportunity now is to keep that progress moving forward.
At BeOne, we’re committed to building evidence that is deep and broad enough to support confident treatment decisions across the full range of patients with CLL.
We’re helping move that progress forward. Read more: https://t.co/TZBVJYlfwG
#CLL #BeOneAgainstCancer
Cancer treatments have never held more promise. Why aren’t more patients benefiting from them?
We shared with @USATODAY how chronic lymphocytic leukemia (CLL) highlights the gap between scientific innovation and a healthcare system that has failed to keep pace, and what it will take to help more patients get the right care at the right time.
Read the full article, in partnership with Mediaplanet and hosted by USA TODAY: https://t.co/YerIsMvgvc
In chronic lymphocytic leukemia (CLL), a headline result is just the beginning.
At BeOne, we believe what matters is whether the benefit holds over time, and whether the evidence reflects the full spectrum of patients.
In a disease where patients may live with their diagnosis for decades, long-term follow-up shouldn’t be an outlier. It is the evidence standard that should shape frontline treatment decisions.
Learn more about how we’re helping build momentum in CLL treatment: https://t.co/oMiWZZHx6O
#CLL #BeOneAgainstCancer
#News for #Investors and #Media: This week, we announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for our PD-1 inhibitor combination therapy for the first-line recurrent or metastatic nasopharyngeal carcinoma.
This milestone marks an important step in the reimbursement pathway, bringing eligible patients one step closer to publicly funded access to our PD-1 inhibitor in Canada.
Read the full announcement: https://t.co/zAsRFfAwRR
#Oncology #BeOneInnovator
The latest installment of Expert Answers in HER2+ Gastroesophageal Cancer features Dr. Jaffer Ajani discussing advances in HER2- targeted therapies.
Learn more: https://t.co/A1kS3lMV9o
#GastroesophagealCancer#HER2#Biomarkers#CancerResearch
Scientific progress has transformed what’s possible for people living with chronic lymphocytic leukemia (CLL). But the healthcare system has failed to keep pace with science.
Too many patients still face gaps in biomarker testing, CLL expertise, care coordination, insurance coverage and more that stand between them and the latest advances in CLL care.
That’s why we partnered with @News_CRA and the broader blood cancer community on a first-of-its-kind national assessment of the CLL care ecosystem: When Innovation Outpaces Access: Closing the Gap in CLL Care.
The report outlines five actions to help more patients receive the right treatment at the right time:
✅ Expand access to biomarker testing
✅ Improve access to scientifically accurate information
✅ Connect more patients to CLL expertise
✅ Reduce insurance barriers that delay or deny treatment
✅ Increase transparency and promote responsible AI in cancer care
Learn more and download the full report: https://t.co/6rmIsxWfYe
#BloodCancerAwarenessMonth #CLL